Skip to main content
CLDX
NASDAQ Life Sciences

Celldex Scraps Atopic Dermatitis Program After Phase 2 Itch Data Miss

Tom Rudovsky · Reported by Benzinga
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$27.5
Mkt Cap
$2.158B
52W Low
$22.33
52W High
$45.14
52W Position info
23% above low
Off High info
39% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

CLDX sits 23% above its 52-week low of $22.33 on light trading volume (0.2× avg).

Summary

Celldex is walking away from barzolvolimab in moderate-to-severe atopic dermatitis after the Phase 2 trial failed to beat placebo on itch. At Week 16 the 300 mg dose cut PP-NRS scores 29.2% and the 150 mg dose 16.2%, versus 19.5% for placebo — neither was statistically significant, and EASI and IGA secondary endpoints also failed to separate. Extending treatment to Week 32 added nothing. This follows the November 19 disclosure of the primary endpoint miss and is the second itch-program setback this year, after the July prurigo nodularis failure. The AD indication is now gone, but the core thesis rests on chronic spontaneous urticaria, where Phase 3 EMBARQ data read out positive in September and a BLA is planned for 2027; cold urticaria and symptomatic dermographism Phase 3 enrollment continues. Shares were down 0.25% premarket at $27.89, a muted reaction that suggests the miss was largely priced in.

At the time of this announcement, CLDX was trading at $27.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $22.33 to $45.14. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Benzinga.


Price Chart

Share this article

Copied!

CLDX - Latest Insights

CLDX
Nov 19, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $27.00
Real-time Price: $27.50 info
Change: +$0.500 (+2%) info
Market Cap: $2.162B info
CLDX
Sep 22, 2026, 8:36 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $32.00
Real-time Price: $27.50 info
Change: -$4.50 (-14%) info
Market Cap: $2.162B info
CLDX
Sep 22, 2026, 7:09 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $45.89
Real-time Price: $27.50 info
Change: -$18.39 (-40%) info
Market Cap: $2.162B info
CLDX
Sep 22, 2026, 6:59 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $38.46
Real-time Price: $27.50 info
Change: -$10.96 (-28%) info
Market Cap: $2.162B info
CLDX
Aug 06, 2026, 4:26 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $41.37
Real-time Price: $27.50 info
Change: -$13.87 (-34%) info
Market Cap: $2.162B info